{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":20,"n_cols":5,"rows_kept":20,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[13,2,13,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910632492503321"]
[null,null,"Autore",null,"Shelby Amanda M"]
[null,null,"Titolo",null,"Small Animal Anesthesia Techniques"]
[null,null,"Pubbl/distr/stampa",null,"Newark : , : John Wiley & Sons, Incorporated, , 2022"]
[{"$nulls":4},"©2023"]
[null,null,"ISBN",null,"1-119-71086-3"]
[{"$nulls":4},"1-119-71084-7"]
[null,null,"Edizione",null,"[2nd ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (435 pages)"]
[null,null,"Disciplina",null,"636.089796"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Cover Page -- Title Page -- Copyright Page -- Contents -- List of Contributors -- Preface -- Acknowledgments -- About the companion website -- Section I: General topics in anesthesia and analgesia -- Chapter 1 Anesthetic process -- I. Preanesthetic workup -- A. Patient workup -- II. Factors involved in creating an anesthetic plan -- A. Patient species problem list -- B. Specific patient problem list -- C. Inhaled anesthesia and drug-induced problem list -- D. Procedure-driven problem list -- E. Anesthetic morbidity and mortality -- F. Anesthesia checklist -- III. Patient preparation -- IV. Premedication -- V. Induction -- A. Intubation -- VI. Anesthetic maintenance -- A. Options for anesthetic maintenance -- B. Fluid therapy -- VII. Recovery from anesthesia in the clinical setting -- A. Timeline and signs of recovery at home -- B. Communications about returning home -- References -- Chapter 2 Anesthesia equipment and monitoring -- I. Gas pressures in a hospital system -- II. Setting up the anesthesia machine -- A. Selecting a breathing system -- B. Reservoir bag -- C. Troubleshooting leaks (Box 2.7) -- III. Barotrauma -- A. Temporary occlusion device (Figure 2.4) -- B. Pressure relief valves (Table 2.3, Figure 2.5) -- IV. Mechanical ventilation (MV) or intermittent positive pressure ventilation (IPPV) -- A. Classification of ventilators -- B. Optional ventilator features -- C. Troubleshooting common problems of a mechanical ventilator -- V. Monitoring equipment -- A. Circulatory system -- B. Ventilation -- C. Thermoregulation -- D. Blood gas analysis -- References -- Chapter 3 Adverse events/anesthetic complications -- I. Cardiovascular complications -- A. Sinus "]
[{"$nulls":4},"bradycardia -- B. Atrial ventricular (AV) block -- C. Bundle branch blocks -- D. Atrial flutter and fibrillation -- E. Ventricular arrhythmias."]
[{"$nulls":4},"F. Cardiac arrest rhythms: asystole, pulseless electrical activity (PEA), and ventricular fibrillation (VF) -- G. Isorhythmic dissociation -- II. Blood pressure -- A. Hypertension -- B. Hypotension -- C. Blood loss/hemorrhage -- III. Respiratory complications -- A. Hyperventilation (hypocapnia) -- B. Hypoventilation (hypercapnia) -- C. Hypoxemia/inappropriate P:F ratio -- D. Pulmonary thromboembolism -- E. Pneumothorax -- F. Postanesthetic aspiration pneumonia -- G. Respiratory distress or arrest -- IV. Acid-base disturbances -- A. Metabolic acidosis -- B. Metabolic alkalosis -- C. Respiratory acidosis -- D. Respiratory alkalosis -- V. Electrolyte disturbances -- A. Calcium -- B. Potassium -- C. Sodium -- VI. Glycemic control -- A. Hyperglycemia -- B. Hypoglycemia -- VII. Other complications -- A. Anaphylaxis/anaphylactoid reaction -- B. Gastrointestinal dysfunction secondary to anesthesia -- C. Hyperthermia -- D. Hypothermia -- E. Noxious stimuli (\"breakthrough pain\" or \"arousal\") -- F. Recovery complications -- References -- Chapter 4 Anesthetic considerations for specific procedures -- I. Soft tissue surgeries -- A. Abdominal exploratory (exploratory laparotomy) -- B. Amputations (digits, forelimb, hindlimb, tail) -- C. Superficial mass removal -- D. Head and neck procedures -- E. Perianal surgeries (anal sacculectomy, perianal fistula, vulvoplasty) -- F. Reproductive procedures -- G. Thoracotomy procedures -- H. Urological procedures (cystotomy, perineal urethrostomy [PU]) -- II. Orthopedic/neurology procedures -- A. Orthopedic procedures on the head -- B. Thoracic limb orthopedic procedures -- C. Hindlimb orthopedic procedures -- D. Dorsal hemilaminectomy -- E. Ventral slot -- III. Scoping procedures -- A. Bronchoscopy and bronchial alveolar lavage (BAL) (Box 4.33) -- B. Rhinoscopy and biopsy (Box 4.34)."]
[{"$nulls":4},"C. Gastroscopy (upper/lower GI) (Box 4.35) -- References -- Chapter 5 Anesthesia in patients with concurrent disease -- I. Cardiovascular disease -- A. Conduction and rhythm disturbances -- B. Structural abnormalities -- II. Endocrine diseases -- A. Diabetes insipidus -- B. Diabetes mellitus -- C. Hyperadrenocorticism (Cushing disease) -- D. Hypoadrenocorticism (Addison's disease) [26] -- E. Hyperthyroidism -- F. Hypothyroidism -- G. Pheochromocytoma -- H. Insulinoma -- III. Hepatic function diseases -- IV. Neurological disorders: Intracranial disease -- V. Renal insufficiencies -- VI. Respiratory/pulmonary disease -- A. Upper airway disease -- B. Lower airway disease -- C. Space-occupying respiratory disease -- VII. Other conditions that influence anesthesia -- A. Age -- B. Body condition -- C. Pregnancy -- D. Shock/trauma patient -- References -- Chapter 6 Anesthesia and analgesia in the exotic patient -- I. Common exotic mammals -- A. Ferrets -- B. Hedgehogs -- C. Pot-bellied pigs (PBPs) -- D. Rabbits -- E. Rodents (chinchillas, gerbils, guinea pigs, hamsters, mice, rats) -- II. Avians -- III. Reptiles -- References -- Chapter 7 Nonopioid analgesia alternatives and locoregional blocks -- I. Nonopioid analgesic constant-rate infusions -- A. Ketamine -- B. Dexmedetomidine -- C. Lidocaine -- II. Oral gabapentinoids -- III. Psychotropic drugs -- IV. Cannabinoids -- V. Antiinflammatories -- VI. Nonpharmacological pain therapy -- A. Acupuncture -- B. Physical rehabilitation -- VII. Local-regional anesthetic techniques -- A. Local anesthetics (LAs) -- B. Equipment used for local-regional anesthesia -- C. Local-regional anesthesia -- D. Peripheral nerve blocks -- VIII. Conclusion -- References -- Section II: Drug formulary -- I. Acepromazine maleate phenothiazine -- II. Albuterol intermediate acting beta-2-adrenergicagonist."]
[{"$nulls":4},"III. Alfaxalone synthetic neuroactive steroid with anesthetic properties -- IV. Amantadine oral NMDA antagonist analgesic -- V. Aminocaproic acid -- VI. Amiodarone class 3 antiarrhythmic drug -- VII. Atenolol beta-1-adrendergicantagonist -- VIII. Atipamezole alpha-2antagonist -- IX. Atracurium nondepolarizing neuromuscular blocking agent -- X. Atropine anticholinergic, parasympatholytic agent -- XI. Bupivacaine (standard formulation) local anesthetic -- XII. Bupivacaine (liposomal encapsulated) local anesthetic -- XIII. Buprenorphine (standard formulation) partial mu agonist opioid -- XIV. Buprenorphine high-concentrationformulation of buprenorphine [1.8 mg/mL] -- XV. Buprenorphine SR sustained-release(SR) buprenorphine -- XVI. Butorphanol mu antagonist, kappa agonist opioid -- XVII. Calcium gluconate calcium supplement -- XVIII. Carprofen NSAID -- XIX. Cisatracurium nondepolarizing neuromuscular blocking agent -- XX. Dantrolene muscle relaxant -- XXI. Deracoxib NSAID, selective COX-2inhibitor -- XXII. Desflurane inhalant anesthetic -- XXIII. Desmopressin (DDAVP) arginine vasopressin (AVP) analogue -- XXIV. Dexamethasone sodium phosphate (SP) corticosteroid -- XXV. Dexmedetomidine alpha-2agonist -- XXVI. Dextrose supplement -- XXVII. Diazepam benzodiazepine -- XXVIII. Diphenhydramine antihistamine -- XXIX. Dobutamine positive inotrope -- XXX. Dopamine endogenous catecholamine and positive inotrope -- XXXI. Doxapram respiratory stimulant -- XXXII. Ephedrine synthetic noncatecholamine inotropic and vasopressor agent -- XXXIII. Epinephrine (adrenaline) endogenous catecholamine -- XXXIV. Eutectic mixture of lidocaine and prilocaine topical local anesthetic -- XXXV. Esmolol beta receptor antagonist -- XXXVI. Etomidate induction agent -- XXXVII. Famotidine H2 receptor antagonist -- XXXVIII. Fentanyl full mu agonist opioid."]
[{"$nulls":4},"XXXIX. Flumazenil benzodiazepine antagonist -- XL. Furosemide diuretic -- XLI. Gabapentin anticonvulsant, nonopioid analgesic -- XLII. Grapiprant noncyclooxygenase-inhibitingNSAID -- XLIII. Glycopyrrolate anticholinergic -- XLIV. Hydromorphone full mu agonist opioid -- XLV. Hydroxyethyl starch, \"Hetastarch 6%\" colloid fluid -- XLVI. Isoflurane inhalant anesthetic -- XLVII. Isolyte® -- XLVIII. Isoproterenol beta agonist -- XLIX. Ketamine NMDA antagonist and dissociative anesthetic -- L. Ketoprofen NSAID -- LI. Lactated Ringer's Solution (LRS) balanced electrolyte, isotonic crystalloid solution -- LII. Lidocaine Na+ channel blocker, local anesthetic -- LIII. Mannitol osmotic diuretic -- LIV. Maropitant neurokinin-1 receptor antagonist -- LV. Meloxicam NSAID -- LVI. Meperidine full agonist opioid -- LVII. Mepivacaine local anesthetic -- LVIII. Methadone full agonist opioid -- LIX. Midazolam benzodiazepine -- LX. Morphine full mu agonist opioid -- LXI. Naloxone opioid antagonist -- LXII. Neostigmine nondepolarizing neuromuscular blocking antagonist -- LXIII. Nitroprusside alpha antagonist -- LXIV. Norepinephrine endogenous catecholamine, vasopressor -- LXV. Normosol® balanced electrolyte, isotonic crystalloid solution -- LXVI. Pancuronium nondepolarizing neuromuscular blocking agent -- LXVII. Pantoprazole proton pump inhibitor -- LXVIII. Pentobarbital sodium barbiturate -- LXIX. Phenoxybenzamine alpha receptor blocker -- LXX. Phenylephrine vasopressor -- LXXI. Plasma-Lyte® 148 balanced electrolyte, isotonic crystalloid solution -- LXXII. Potassium chloride (KCl) electrolyte supplement -- LXXIII. Proparacaine 0.5% local anesthetic -- LXXIV. Procainamide class IA antiarrhythmic -- LXXV. Propofol induction agent -- LXXVI. Propranolol nonselective beta-blocker -- LXXVII. Remifentanil full agonist opioid -- LXXVIII. Robenacoxib NSAID."]
[{"$nulls":4},"LXXIX. Ropivacaine local anesthetic."]